Oxford BioMedica (OXB) AI Stock Analysis

• Market Cap: £315.88M
• Dividend Yield: N/A
• Average Volume (3M): 169.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 43.84%
• EPS Growth: 74.88%
• Country: UK
• Employees: 850
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 105,998,460
• 10 Day Avg. Volume: 167,001
• 30 Day Avg. Volume: 169,524
• PEG Ratio: -0.10
• Price to Book (P/B): 5.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £650.33
• Price Target Upside: 111.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Oxford BioMedica's moderate overall score reflects strong revenue growth and strategic expansion efforts, yet significant profitability and cash flow challenges remain. The positive outlook from the earnings call contributes to optimism, but valuation concerns and high leverage continue to pose risks. Technical indicators provide a stable outlook, balancing the company's financial and operational challenges.

Positive Factors

Financial Outlook

OXB is on track to deliver EBITDA profitability in 2025, supported by a healthy contracted order book.

Revenue Growth

OXB delivered revenues of £128.8m, representing 44% growth YoY.

Negative Factors

Macroeconomic Concerns

There is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.

Oxford BioMedica Business Overview & Revenue Model

Company Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioMedica generates revenue through multiple streams, primarily centered around its expertise in lentiviral vector technology. The company earns money by collaborating with pharmaceutical and biotechnology companies, providing them with development and manufacturing services for gene and cell therapy products. This includes licensing its proprietary technologies and platforms, as well as entering into strategic partnerships and agreements that often include upfront payments, milestone payments, and royalties on product sales. Additionally, OXB may invest in proprietary drug development, aiming to generate future revenue through the commercialization of its own therapeutic products. Significant partnerships with major industry players such as Novartis contribute to its earnings by leveraging OXB's unique capabilities in vector production and development.

Oxford BioMedica Financial Statement Overview

Summary

Oxford BioMedica shows strong revenue growth but faces persistent profitability and cash flow challenges. The high debt level relative to equity could impact financial flexibility. Improvements in cash generation and debt management are necessary to stabilize the financial position.

Income Statement

Oxford BioMedica's income statement reveals significant volatility in revenue and net income over the years. The most recent year shows a positive revenue growth of 43.84% from the previous year, but the company continues to face profitability challenges with a negative net profit margin of -33.53% and a negative gross profit margin of 40.65%. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

The balance sheet analysis shows a high level of debt relative to equity, with a debt-to-equity ratio of 1.91, posing a risk to financial stability. However, the equity ratio stands at 24.62%, reflecting some level of financial cushioning. Return on equity is negative due to sustained losses, highlighting profitability concerns.

Cash Flow

Cash flow analysis indicates negative free cash flow growth and operating cash flow, pointing to liquidity issues. The free cash flow to net income ratio is 1.35, suggesting that the company is not generating sufficient free cash flow to cover its net losses, which could put pressure on future operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
128.80M	89.54M	139.99M	142.80M	87.73M
	Gross Profit
53.02M	39.73M	69.18M	82.64M	46.07M
	EBIT
-39.38M	-184.17M	-51.56M	20.77M	-4.83M
	EBITDA
-14.33M	-148.62M	-10.86M	33.22M	3.92M
	Net Income Common Stockholders
-43.19M	-157.49M	-45.16M	19.01M	-6.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
60.65M	103.72M	141.31M	109.02M	46.98M
	Total Assets
231.64M	252.34M	460.18M	237.23M	183.93M
	Total Debt
108.76M	111.46M	114.28M	9.34M	13.85M
	Net Debt
48.11M	7.74M	-27.00M	-99.60M	-32.90M
	Total Liabilities
171.16M	174.51M	223.99M	49.89M	71.18M
	Stockholders Equity
57.05M	74.01M	204.65M	187.34M	112.75M
Cash Flow		Free Cash Flow
-58.12M	-38.35M	-28.91M	15.99M	-10.24M
	Operating Cash Flow
-50.63M	-28.52M	-12.62M	25.45M	3.12M
	Investing Cash Flow
5.63M	2.81M	-56.46M	-9.46M	-10.80M
	Financing Cash Flow
2.91M	-12.70M	98.62M	46.21M	38.19M

Oxford BioMedica Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 307.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OXB, the sentiment is Neutral. The current price of 307.5 is above the 20-day moving average (MA) of 296.00, above the 50-day MA of 290.98, and below the 200-day MA of 363.55, indicating a neutral trend. The MACD of 1.40 indicates Negative momentum. The RSI at 56.67 is Neutral, neither overbought nor oversold. The STOCH value of 81.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:OXB.

Oxford BioMedica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRTC	58 Neutral	£307.44M	7.90	11.74%	―	38.80%	―
ONT	56 Neutral	£1.16B	―	-23.77%	―	7.97%	12.94%
OXB	54 Neutral	£315.88M	―	-66.23%	―	43.84%	74.88%
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
SCLP	46 Neutral	£95.90M	―	167.16%	―	-100.00%	-23.91%

Oxford BioMedica Corporate Events

Oxford Biomedica Awards Share Options to Leadership

Oxford Biomedica has announced the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan. These grants, aimed at aligning with the company’s growth strategy, focus on key metrics such as EBITDA margin and revenue growth, which are crucial for stakeholders and reflect the company’s commitment to incentivizing its leadership team.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on GB:OXB Stock

According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.

Oxford BioMedica scores moderately due to strong revenue growth and strategic expansions, balanced by operational profitability challenges and high leverage. Technical indicators show stable trends, but valuation metrics highlight profitability concerns. Positive corporate events and earnings call outlook provide optimism but underscore the need for improved cash flow and debt management.

To see Spark’s full report on GB:OXB stock, click here.

Oxford Biomedica Announces Share Transaction by Associated Person

Oxford Biomedica announced that Pippa Radcliffe, closely associated with the company’s Chief Innovation Officer, Dr. Kyriacos Mitrophanous, exercised 1,209 options and sold 1,209 shares at £2.9785 per share. This transaction, compliant with EU Market Abuse Regulation, reflects internal financial activities and may impact stakeholders’ perceptions of the company’s governance and financial health.

Oxford BioMedica Sees Change in Major Shareholder Voting Rights

Oxford BioMedica PLC has announced a change in its major shareholders, with Briarwood Chase Management LLC acquiring a significant increase in voting rights, now holding 12.019% of the total. This acquisition indicates a strengthened position for Briarwood Chase Management in the company, potentially influencing future strategic decisions and impacting stakeholder interests.

Oxford Biomedica Announces 2025 Annual General Meeting Details

Oxford Biomedica PLC has announced the notice of its Annual General Meeting (AGM) for 2025, which will be held on 11 June at its Oxford offices. The company has made the AGM notice and its 2024 Annual Report available to shareholders and submitted them to the Financial Conduct Authority for public access. This announcement is part of OXB’s ongoing commitment to transparency and stakeholder engagement, reflecting its strategic focus on maintaining strong governance and communication with its investors.

Oxford BioMedica Sees Stake Increase by Briarwood Chase Management

Oxford BioMedica PLC has announced a change in its voting rights, with Briarwood Chase Management LLC increasing its stake to 11.03% from a previous 10.54%. This acquisition of voting rights signifies a significant shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder interests.

Oxford BioMedica Reports Robust 2024 Financial Performance and Strategic Expansion

Oxford BioMedica reported strong financial results for 2024, with a 44% increase in revenue to £128.8 million and an 81% organic growth rate. The company’s strategic expansion, including the acquisition of ABL Europe, has bolstered its global operations, particularly in viral vector platforms. The company achieved an operating EBITDA profit in the second half of 2024 and anticipates profitability for FY 2025. The growth reflects increased demand across all vector segments, with a notable rise in contracted client orders, signaling robust commercial momentum and positioning OXB for continued success in the cell and gene therapy market.

Briarwood Chase Increases Stake in Oxford BioMedica

Oxford BioMedica PLC has announced a significant change in its shareholder structure, as Briarwood Chase Management LLC has increased its voting rights in the company to 10.54%, up from a previous 5.12%. This acquisition of voting rights highlights Briarwood Chase’s growing influence within the company, potentially impacting future strategic decisions and stakeholder interests.

Oxford Biomedica’s Colin Bond Joins Faron Pharmaceuticals as Non-Executive Director

Oxford Biomedica PLC announced the appointment of Colin Bond, a Non-Executive Director, to a similar role at Faron Pharmaceuticals Ltd, an AIM-listed company. This move reflects OXB’s strategic positioning within the cell and gene therapy industry, potentially strengthening its network and influence through leadership roles in related companies.

Oxford Biomedica Announces Total Voting Rights

Oxford Biomedica PLC announced its total voting rights as of February 28, 2025, with an issued share capital consisting of 105,975,816 ordinary shares. This figure is significant for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules, impacting how they manage their investments.

Oxford Biomedica to Present at Global Healthcare Conference

Oxford Biomedica announced that its Chief Financial Officer, Dr. Lucinda Crabtree, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025. This participation highlights OXB’s active engagement in the global healthcare community and reinforces its position as a leader in the cell and gene therapy industry.

M&G Plc Increases Stake in Oxford BioMedica

Oxford BioMedica PLC has announced that M&G Plc has increased its voting rights in the company to 5.024244% as of February 19, 2025. This acquisition of voting rights by M&G Plc indicates a strengthened position in Oxford BioMedica, potentially impacting the company’s strategic decisions and signaling confidence from a major investor, which could influence the market perception and future stakeholder engagement.

Oxford Biomedica Supports Boehringer Ingelheim’s Cystic Fibrosis Gene Therapy Trial

Oxford Biomedica has announced that its lentiviral vector manufacturing technology will support Boehringer Ingelheim’s new Phase I/II LENTICLAIR™ 1 trial. This trial, evaluating an innovative gene therapy for cystic fibrosis, highlights OXB’s role in the ongoing collaboration with Boehringer Ingelheim, reflecting its reputation as a trusted partner in advancing pioneering gene therapies addressing unmet medical needs.

Oxford BioMedica Announces Change in Major Holdings

Oxford BioMedica PLC announced a change in major holdings, as Ameriprise Financial, Inc., a US-based company, has altered its voting rights in the company. The percentage of voting rights held by Ameriprise Financial decreased from 5.099% to 3.886%, signaling a shift in their investment strategy. This change may impact the company’s shareholder dynamics and influence future decisions, although the specific implications for stakeholders remain unspecified.